AAVXF Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat DBV Technologies SA's return on equity of -280.59%.

Abivax SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $40.03 which suggests that it could grow by 75.88%. Given that DBV Technologies SA has higher upside potential than Abivax SA, analysts believe DBV Technologies SA is more attractive than Abivax SA.

Abivax SA has a beta of 1.286, which suggesting that the stock is 28.582% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Abivax SA's net income of -$179.2M is lower than DBV Technologies SA's net income of -$33M. Notably, Abivax SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Abivax SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $5.15 which suggests that it could grow by 194.51%. Given that Innate Pharma SA has higher upside potential than Abivax SA, analysts believe Innate Pharma SA is more attractive than Abivax SA.

Abivax SA has a beta of 1.286, which suggesting that the stock is 28.582% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.148%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Innate Pharma SA quarterly revenues of --. Abivax SA's net income of -$179.2M is higher than Innate Pharma SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 22.60x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Inventiva SA's return on equity of --.

Abivax SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 264.21%. Given that Inventiva SA has higher upside potential than Abivax SA, analysts believe Inventiva SA is more attractive than Abivax SA.

Abivax SA has a beta of 1.286, which suggesting that the stock is 28.582% more volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Inventiva SA quarterly revenues of --. Abivax SA's net income of -$179.2M is higher than Inventiva SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 24.51x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -- compared to Abivax SA's net margin of --. Abivax SA's return on equity of -- beat Nanobiotix SA's return on equity of --.

Abivax SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nanobiotix SA has an analysts' consensus of $14.75 which suggests that it could fall by -33.34%. Given that Nanobiotix SA has higher upside potential than Abivax SA, analysts believe Nanobiotix SA is more attractive than Abivax SA.

Abivax SA has a beta of 1.286, which suggesting that the stock is 28.582% more volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Abivax SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abivax SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Abivax SA quarterly revenues are --, which are larger than Nanobiotix SA quarterly revenues of --. Abivax SA's net income of -$179.2M is higher than Nanobiotix SA's net income of --. Notably, Abivax SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abivax SA is -- versus 30.87x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.